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BETWEEN ADVOCACY AND RESPONSIBILITY:
THE CHALLENGE OF BIOTECHNOLOGY
FOR INTERNATIONAL LAW
James Buchanan*
Let me begin by saying that I write as a philosopher and ethicist not
as an expert in international law. What I argue is that those working in the
fields of international law or international legal theory, as it pertains to issues
of biotechnology and biodiversity, cannot avoid confronting a range of
philosophical and ethical questions. I will frame these issues in terms of
"advocacy" and "responsibility." The distinction between "advocacy" and
"responsibility" is not meant to imply that advocacy is not a matter of
responsibility, rather I will use the term "responsibility" here to refer to those
issues and commitments which go beyond the more immediate demands of
advocacy. Another way to frame these concepts might be in terms of the
distinction between the professional responsibility of advocacy and the larger
questions of social responsibility which take us into the domain of ethics.
The fundamental point I pursue is that biotechnology presents special
problems for international law. Even though virtually every case is without
precedent, the precedents which are now being established will have profound
effects in the future. It is this future-orientation which raises profound ethical
questions. Given that biotechnology is an incipient technology that will have
dramatic, yet unknown, impacts upon the future, the larger questions of social
and environmental responsibility cannot be avoided.
While both biotechnology and biodiversity have emerged as important
domestic concerns in the United States and Europe, it is in the context of
international agreements and international law that we see the real issues
emerge. International law is based upon the interpretation of conventions,
treaties, and agreements between nations and institutions. Two agreements,
crucial to the future of biotechnology, are those signed at the United Nations
Conference on Environment and Development (UNCED) and negotiated
under the General Agreement on Tariffs and Trade (GATT). What is
* Dr. James Buchanan teaches at the Hong Kong University of Science and Technology. His
background concerns ethics with a special focus on the social and environmental concerns of
science and technology. His current research concerns intellectual property rights, particularly
as they pertain to biotechnology and biodiversity.
Various sections and topics contained in this article have been presented as lectures or
as part of discussions during 1993 and 1994 in Hong Kong; Rio de Janiero, Brazil; New Delhi,
India; Peniscola and Barcelona, Spain; Geneva, Switzerland; Washington, D.C., and Concord,
N.H. It has benefitted greatly from the comments, corrections and questions raised on those
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interesting and important for our discussion is that, within these two sets of
agreements, we find competing visions for the next century. At the heart of
these visions is biotechnology and biodiversity.
UNCED and GATT share much in common. They are the two
largest international agreements signed within this generation. Both strive to
be holistic and comprehensive in setting an agenda for the present and future
world community. Each frames the future in the context of economics,
particularly the economics of the relationship between developed and
developing countries. Finally, both are concerned about regulating the use and
distribution of resources and technologies.
What is disturbing about these crucial documents is what they do not
share. There is a fundamental conflict between their respective visions of the
future and neither takes into account the other. One way to frame this
conflict is to look at the way the future development of biotechnology is
viewed in each of these agreements.
Any kind of detailed analysis of these two agreements is beyond the
scope of this article; however, it is worth summarizing their basic orientations
because these represent the cornerstone of their future. The UNCED process,
stretching over many years, attempted to tie two of the most pressing
international issues together: the environment and economic development.
These competing and related concepts are framed in terms of a balance
between the environment, economic development in developed countries, and
economic development in the developing world. The phrase,"sustainable
development," reflects this set of relationships.
Sustainable development is a new, more holistic, way of framing the
problem and not the solution. It recognizes that the issues of the environment
and poverty are linked and can only be approached globally and
generationally. Sustainable development is first and foremost about the future:
preserving resources and a quality of life for future generations while
attempting to deal with the problems faced by the present generation. The
importance given both to future generations and to developing economies
within the UNCED documents was the source of much hostility from global
business interests with biotechnology being an excellent case in point.
The background and history of biotechnology in the UNCED process
is crucial to understanding the dialectic process. I say process because one
cannot simply look at what occurred at the final meetings of UNCED in Rio
de Janiero held from June 1 - 12, 1992. One must begin the study with the
first Preparatory Conference in Nairobi in August 1990, wherein
biotechnology was slated to have been the subject of one of the conventions.1
1. See THE EARTH SUMMiT: THE UNITED NATIONS CONFERENCE ON ENVIRONMENT (Stanley
Johnson ed., 1993) [hereinafter Johnson]. The documents from the Prepatory Conferences used
here were obtained through Internet. The final UNCED documents are available at The United
Nations Environmental Programme, Intergovernmental Negotiating Committee.
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Conventions are the most powerful documents negotiated in the UNCED
process. Two conventions were signed in Nairobi, Kenya: the Convention
on Biological Diversity2 and the Convention on Climate Change.3  The
history of biotechnology in the UNCED process is the history of its
elimination. At the first Preparatory conference in Nairobi, pressures exerted
primarily by the United States, with support from Japan, and Germany,
resulted in biotechnology being downgraded from the status of "convention"
to that of an issue connected with biodiversity. This pressure was maintained
throughout Preparatory Conferences 2, 34 and 4,5 as well as in the final
negotiations in Rio, until biotechnology was taken up as an issue only in
Articles 15 and 19.6 It was addressed indirectly as an issue in Articles 16-18
of the Convention on Biological Diversity,7 and Chapter 16 of Agenda 21.8
The U.S. concern throughout the process was the elimination of
anything that would regulate the growth of this new industry. It was
relatively easy to do this because UNCED was dealing with a vast range of
complex issues, many with more immediate impact upon the developing
nations. Biotechnology was either lost in the mix or became a negotiating
chip used to get concessions on other issues. Non-governmental organizations,
which have never had any well-defined position on biotechnology, did little
to press for greater attention to biotechnology. Thus, the fact that UNCED
was establishing certain fundamental principles and definitions, or neglecting
issues which will have direct and potentially dramatic effects upon the
environment was missed by most countries.' Only those countries which
2. Id. at 81-102.
3. Id. at 57-80.
4. See Johnson, supra note 1. PreCom II was Held in Geneva March/April, 1991. PreCom II
was held in Geneva August, 1991. PreCom IV was held in New York March, 1992.
5. See Johnson, supra note 1, at 88-90.
6. Id. at 89-90.
7. Id. at 293-304.
8. See infra note 9. This is also the interpretation of the Non-governmental Organization
Biotechnology Task Force.
9. The ad hoc Non-Governmental Organization (NGO) Biotechnology Task Force led by the
representatives of the Biotechnology Working Group of the United States, produced a Critique
of Chapter 16 and Agenda 21 and a list of thirteen principles concerning biotechnology which
attempt to establish some limitations for its development and use as well as for the equitable
distribution of profits and technology transfer.
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presently control or seek to continue to control the regulation (or lack
thereo) on biotechnology well understood that biotechnology was a major
issue. 0
By the "Earth Summit, "" most of the issues and questions representing
the interests of the developing countries and environmentalists had been
eliminated. The issues that remained came suspiciously close to mirroring the
bioindustry's own positions and interests. We can find those interests
expressed in documents supplied to the UNCED negotiators by the
International Bioindustry Forum (IBF)."2  The IBF is an umbrella
organization representing the views of its member organizations: The Senior
Biotechnology Advisory Group (Europe), the Japan Bioindustry Association,
the Industrial Biotechnology Association (the United States), and the Industrial
Biotechnology Association of Canada.
One such document entitled, "Policies for Sustainable Development:
The Role of Biotechnology," expresses an uncritical view of the social and
environmental impacts of biotechnology. 3 The following statements are
drawn from that document and reflect this view:
New technologies and their applications are essential for
human welfare, for worldwide sustainable growth, social
development and our natural environment.... The
application of new technologies will aid all countries of the
world.... Based on experience to date, the benefits of modern
biotechnology far outweigh conjectural concerns and
therefore must have appropriate support.... Modern
biotechnology will help to maintain biodiversity and to
ensure genetic diversity.... Biotechnology will (provide)
extensive environmental benefits for sustainable growth.14
The document further maintains that genetically manipulated
organisms are "natural" (not artificial) and that they are "improvements" upon
10. This conclusion is based upon personal observations of the negotiations, as well as interviews
with other non-governmental groups.
11. Earth Summit refers to The United Nation Conference on Environment and Development
held June 1-12 in Rio de Janiero, Brazil.
12. See infra note 14, POLICIES FOR SUSTAINABLE DEVELOPMENT.
13. See infra note 14, POLICIES FOR SusTAINABLE DEvELOPMENT.
14. INTERNAIONAL BIOINDUTrKY FORUM (IBF), POLICIES FOR SUSTAINABLE DEVELOPMENT:
THE ROLE OF BIOTECHNOLOGY, 3-10 (1992)(document was obtained from the NGO
Biotechnology Task Force in Rio).
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unmodified organisms because of their increased "efficiency."1 5  It
characterizes those voices which have raised cautionary or critical concerns
about biotechnology as "unfounded" and "conjectural" while listing all of the
future benefits of biotechnology as if they were facts.16
It is reasonable for the bioindustry to vigorously defend its own
position. However, when we compare the IBF document to Chapter 16 of
Agenda 21, entitled Environmentally Sound Management of Biotechnology,7 we
find the same uncritical perspective. The UNCED document goes to great
lengths to present biotechnology as a solution to the world's social and
environmental problems. The "Introduction" begins by telling us that
biotechnology "promises to make a significant contribution in enabling the
development...." of several areas, such as health care, affording food security
via sustainable agricultural practice, improving supplies of drinkable water,
increasing the efficiency of the industrial development processes for
transforming raw materials, and working toward the detoxification of
hazardous waste.18  It proceeds that "biotechnology also offers new
opportunities for global partnerships ... " especially between countries of the
South which are "rich in biological resources [including genetic resources],"
and countries of the North which have the technological expertise "to
transform biological resources so that they serve the needs of sustainable
development."19 It also seeks to "engender public trust and confidence" in
biotechnology.20  Throughout the document it refers to the use of
biotechnology to "improve" or "enhance" life forms.
21
Sections 16.2-16.31, which comprise the bulk of the document,
provide a relatively conclusive list of sustainable ways in which biotechnology
might be used. However, only Sections 16.32-16.42 address the issues of
15. Id. at 8.
16. Id. at 9.
17. Environmentally Sound Management ofBiotechnology, U.N. Conference on Environment and
Development [UNCED], Agenda Item 21, Chapter 16, June 12, 1992; see Johnson supra note 1,
at 293-304.
18. Environmentally Sound Management ofBiotechnology, U.N. Conference on Environment and
Development [UNCED], Agenda Item 21, Chapter 16, at S 16.1 (1992). See Johnson supra note
1, at 293-94.
19. JOHNSONsupra note 1, at 294.
20. JOHNSONsupra note 1, at 294.
21. JOHNSONpassim, 5 16.1, 16.2, 16.3 at 294-95.
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"enhancing safety and developing international mechanisms for
cooperation."' These sections are weak and neglect the establishment of
legal codes and regulations. Instead, they speak rather vaguely about risk
assessment and risk management. They also make reference to "internationally
agreed principles "" without providing definitions. The sections on
cooperations focus on, without providing any specifics, about seeking to
"promote the development and application of biotechnologies, with special
emphasis upon developing countries."24
No mention is made, nor are any mechanisms established, concerning the
need to "recognize and protect the traditional methods and knowledge of
indigenous people and their communities and ensure their participation in the
economic and commercial benefits arising from developments in
biotechnology.""
Also lacking are specific mechanisms and regulatory structures to deal
with issues such as the release of genetically modified materials and transfer of
technology. Finally, the sections concerning financial assistance are limited
and vague. 6 After reading these provisions, one feels that biotechnology is
a solution to many of the social and environmental problems, and it is
relatively uncomplicated in terms of its impacts.
What is interesting is that, as vague as the language is, it was still too
extreme for the Bush administration. One of the principal reasons cited for
the Administration's refusal to sign the Convention on Biological Diversity
and its refusal to support Agenda 21 was its feeling that commitment to these
agreements would hinder biotechnical growth.27 The long-term commitments
of the Administration to biotechnology are crucial to the internationalization
of this new technology. The attitude is that this incipient technology and the
industry built around it must be protected at all costs. The stakes are huge.
The belief is that the long-term economic recovery of the United States is tied
directly or indirectly to the success of biotechnology. This thinking is based
on the recognition that the United States will never again be a leader in heavy
22. JOHNSON passim, §16.1 at 293.
23. JOHNSONpassim, §16.53(c) at 302.
24. JOHNSON passim, §16.45(a) at 304.
25. JOHNSON passim, §16.45(a)(vi at 304.
26. JOHNSON passim, SS 15.45-16.52 at 304-06.
27. The Convention was signed by the United States on June 4, 1993; see, for prior objections
United Nations Environmental Programme, Intergovernmental Negotiating Committee for a
Convention. See also Johnson passim, supplement on statements filed at signing, June 11, 1993.
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industry, which has all gone "South." Nor will it lead the world in the
production of consumer or high-end electronics; most of which has gone to
the "Pacific Rim." The belief that the United States would survive as a
"service economy" has not fulfilled its promise. Thus, in terms of the current
technologies and industries on the horizon, biotechnology (and information
age technologies in general) becomes the primary hope for the future. The
Bush administration estimated that by the turn of the century, biotechnology
will be a fifty billion dollar per year business in the United States. There have
been estimates that by the middle of the next century, as much as fifty to
seventy percent of the GNP of the United States will be directly or indirectly
tied to biotechnology." The United States is presently the world leader in
biotechnology followed by Japan, Germany and Canada. None of these centers
of biotechnology want to see regulations, domestic or international, hinder
their growth.29
We find evidence of that same commitment by the Clinton
administration. Given Vice-President Al Gore's statements that the
bioindustry amounted to "selling the tree of life," it was unexpected that this
administration would take such an uncritical view of the development of this
technology." When the Clinton administration finally signed the
Convention on Biological Diversity,3' it did so with the stipulation that it be
allowed to file an "interpretive statement" along with its signature.12  That
statement was a guarded secret in Washington circles because it reveals the
current administration's position on biotechnology is, in essence, no different
than that of the previous administration. The Administration's main thrust
is that the U.S. will not be bound by anything which might threaten the
development of biotechnology. Its principal concern is to protect the ability
to claim and enforce intellectual property rights, i.e., the ability to patent
genetic material, and to have unrestricted access to the genetic resources. It is
clear that the new administration sees biotechnology as one of the linchpins
in its high-tech approach to the economic future of the United States.
28. See SHELDON KRIMsIY, BIOTECHNIs AND SOCIETY: THE RISE OF INDUSTRIAL GENETIcs
(1991); MARTIN KENNY, BIOTECHNOLOGY: THE UNIVERSITY-INDUSTRIAL COMPLEX, (1986).
29. In fact, even the "forestry initiative" put forward by the United States as what many called
a "peace offering" could be seen as an attempt to bolster biotechnology. The money which the
Bush Administration committed to forestry was primarily for "research" and "inventory." For
the U.S. to inventory the biodiversity of the remaining forests of the world would perform a vital
service for biotechnology by providing it with a list of the potential genetic resources available.
30. See, A. GORE, EARTH IN THE BALANCE: ECOLOGY AND THE HUMAN SPIRT, chs. 7-8 (1992).
31. Signed June 4, 1993.
32. See supra note 27.
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For all of the problems with UNCED, it is still the case that the
orientation of the UNCED agreements is one which sees biological diversity
as having value in and of itself as well as having an economic value. That
intrinsic value confers upon biological diversity certain rights, including the
right to exist. The approach taken by the Biodiversity Convention is one that
calls for the preservation of habitat (more on this below) and, to some degree,
the preservation of the rights of indigenous peoples. Implicit in its vision of
the future is a balancing of the preservation of traditions, cultures and heritages
of various peoples. Social, ethical, and religious concerns must play a role in
the questions of biotechnology and biodiversity. These additional "value"
questions prompted the bioindustry's feeling that UNCED was not the
appropriate context to establish the long-term regulations and ground rules for
the future of biotechnology. It saw GATT as the more appropriate context.
The GATT is, above all, about opening global markets, and creating
a "level playing field" for all those who want to participate in the world's
market. It recognizes that ours is an international economy, therefore, a
definite need exists for a set of internationally recognized regulations according
to which international (and to some degree national) business will be
conducted. Three significant points exist. First, within the GATT, there is
no commitment to sustainable development. Second, where much of the
perspective in the UNCED agreements comes from the developing countries
(although, as I have argued, this is not the case when it comes to
biotechnology), the perspective in the GATT is from the developed countries
and the transnational corporations. Third, where biotechnology and
intellectual property rights were minimized in the UNCED agreements, they
are among the most important issues negotiated in the GATT. As far as the
bioindustry was concerned, the GATT was the right context within which
regulations should be established because the GATT views all of the issues
purely as trade related issues.33
The GATT takes the complex social, ethical and cultural issues which
are behind the UNCED documents and reduces them exclusively to the trade
issue of Intellectual Property Rights (JPR) as Trade Related Intellectual
Property Rights (MIPS). The interests of the GATT do not extend into
other areas of biotechnology. The World Trade Organization (WTO), which
has now been established for the post-GATT negotiations on such issues as the
environment, has shown strong resistance on the part of many of the parties
to deal with these issues. They contend that market issues and environmental
issues need to be separated. This attitude is diametrically opposed to UNCED
and further demonstrates the lack of coordination of these agreements.
33. Initial hopes by many that this would change under the Clinton Administration, which has
sought to negotiate "side agreements" in the NAFTA, have not thus far proven to be the case.
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The real power behind the GATT, transnational corporations, are also
the big winners with the GATT. How one judges whether or not the United
States, or any nation in particular, will benefit from the GATT is a matter of
the degree to which one is convinced that the economic destiny of the nation
is tied to the economic destiny of the transnationals. Once again, the stakes
are huge. The transnationals, such as Bristol Meyers, Squibb, Johnson and
Johnson, Monsanto, Proctor and Gamble, Dupont, Hewlett-Packard, Time-
Warner, and Roche, have all played active roles in "advising" the negotiations.
They recognize that they have much to gain from the worldwide
standardization of patent and copyrights, and the international recognition of
the patenting of life forms.
One way to understand the importance of IPR is to contextualize it
within a fundamental restructuring of society and property within the
emerging information age. For this new age, new lexicons are being
established. The term lexicon is appropriate here even though it basically
refers to a word list. The "lex" portion refers to a certain legal standing of
those words which are on the official list.34 Thus, in addition to a list, the
definitions of the terms in the lexicon are circumscribed. The key term, as far
as biotechnology and biodiversity are concerned, is "information." It is not
just the information super-highway which is fundamental to the information
age, but biotechnology as well. The reference to "information" here does not
mean more information is available, rather a wholesale new description of the
world as "information" and "information systems." The emergence of this new
cybernetic and biotechnical model for understanding the world ties together
two of the great modern-day developments: the computer and biotechnology.
The dominant characteristic of both is the reduction and reorganization of the
world as "information."
The term cybernetics derives from the Greek, "kybernetes" and means
"steersman." Cybernetics was popularized as a term by Norbert Wiener, a
mathematician at the Massachusetts Institute of Technology. He spoke of
cybernetics as being concerned with information and information systems.
Information is
"the name for the content of what is exchanged with the
outer world as we adjust to it, and make our adjustment felt
upon it. The process of receiving and of using information is
the process of our adjusting to the contingencies of the outer
34. I say "legal" standing in the sense that lexicons are often specialized word lists with agreed
upon definitions. See James Buchanan, The Information Age and its New Lexicon: Biotecbnology as
a Case in Point; 16 TECH. Soc'Y 4 (1994).
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environment, and of our living effectively within that
environment."3"
The crucial elements of cybernetics are information and feedback.
Wiener believes that information "belongs among the great concepts of science
such as matter, energy and electric charge."36 Wiener concludes that "society
can only be understood through a study of the messages and the
communications facilities which belong to it."37 Information becomes a new
mode of understanding the world theoretically; however, it also becomes a
new mode of organizing the world practically.
Cybernetics is not concerned with "what a thing is, but how it
behaves."3" Cybernetics describes being-as-relation but reduces the complexity
of relation to one key concept: "information" and its exchange. This is easy
to understand when speaking of computers. However, here the computer
increasingly becomes our model not only for understanding and organizing
society, but it represents the dominant biological model as well. This was
Wiener's intention from the beginning. It is a paradigm shift in the science
of biology. Marjorie Grene tells us that there is a new way of thinking in the
biological sciences which "says in effect: look to engineering, to blueprints and
operational principles for the sources of your theoretical models in biology."3
The key to the forms of engineering that Grene is talking about concerns
information systems. W. H. Thorpe describes living organisms as things
which "absorb and store information, change their behaviour as a result of that
information, and have special organs for detecting, sorting and organizing this
information.... The most important biological discovery of recent years is
the discovery that the processes of life are directed by programmes."40
Programmes are the structures which process and store data; data is
information.
Models of understanding become models of organization. It is here
that international convention and law play a role. They will determine the
35. NORBERT WIENER, THE HUMAN USE OF HUMANS: CYBERNETICS AND SOcm 26 (1954).
36. Id. at 27-28.
37. Id. at 25.
38. Carl Mitcham, Philosophy and Technology, in A GUIDE TO THE CULTURE OF SCIENCE,
TECHNOLOGYAND MEDICINE 316 (Paul Durbin, ed., 1980).
39. MARJORIE GRENE, THE UNDERSTANDING OF NATURE, ESSAYS IN THE PHILOSOPHY OF
BIOLOGY 68 (1974).




lexicons or the way in which we will define and legally circumscribe
"information" for the future. In an information age, information becomes a
principle locus of power and fiduciary exchange. Information becomes not
only the new way of understanding the world, but of organizing it as well.
Not only does computer logic become a model for modes of cognitive
development and organizational structures, but more importantly, information
becomes the newest commodity in the world marketplace. Mark Poster, in
a book which is full of insights into this new model of organization, entitled
The Mode of Information: Poststructuralism and Social Contex, gives us the first
key in understanding this change in the world marketplace.
In the era of industrial capitalism social and natural resources
essential to the production of material goods came under the
control of self-interested private individuals. In the era of the
mode of information the process is at work again. We are
now being convinced that "information" is first a commodity
and second that it is properly controlled by market forces.
41
The key issue of concern is how "information" is defined. Information
is the newest and, arguably, the most important commodity to emerge on the
world's market. It is "information" which is owned as intellectual property;
whether that information is a trade secret or whether it is a genetic code. The
point is, once it is established that information can be owned (in principle) by
means of the recognition of IPR, the next and crucial step is to limit what will
and will not count as "information." Turning back to GATT we can see that
principles are being established which work towards that end.
Section 5, Article 27, entitled "Patentable Subject Matter"42 states:
1) Subject to the provisions of paragraphs 2 and 3
below, patents shall be available for any inventions
whether products or processes, in all fields of
technology, provided that they are new, involve an
inventive step and are capable of industrial
application. Subject to paragraph 4 of Article 65 and
paragraph 3 of the Article, patents shall be available
41. MARKPOSTER, THEMODEOFINFORMATION: POsTsTRuCrURAnsM ANDSOCIALCONTEXr
73 (1990).
42. This is taken from the so-called "Dunkel Draft." Since the GATT is still being negotiated,
things may yet be added or retracted from this section, though indications are that it will remain
substantially as is.
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and patent rights enjoyable without discrimination
as to the place of invention , the field of technology
and whether products are imported or locally
produced.
43
The parts of this section concerning "new," "involve[ing] an
"inventive" step," and [being] "capable of industrial application" are crucial.
One of the issues that has been raised in opposition concerns the status of
"traditional knowledge of indigenous peoples. "4  There are many plant
breeders who, through generations of trial and error, have developed certain
specialized plant varieties. Such plant varieties would not be patentable under
these regimes because they do not meet the stipulations "new" and "involving
an inventive step." But if a scientist obtains some of these seeds and identifies
those special characteristics, it is genetically transformed into "information"
and is thus patentable. Such cases already exist. For example, in West Africa
the local farmers grow a cowpea which is insect resistant. A scientist at the
University of Durban, Angharad Gatehouse, on a trip to West Africa,
obtained some of these seeds. 4 Using biotechnical techniques he discovered
the genetic mechanism which causes them to be insect resistant. He promptly
left the university and joined Agricultural Genetic Company of Cambridge
and they proceeded to apply for a patent for their "invention." The point is
that it was only after the scientists had identified the characteristic genetically
that it became "information" and thus could be owned. It could not be owned
in its traditional form.46  The inscription of "information" within the new
lexicon is limited by terms such as "new" and "inventive step" in order to
benefit only the expertise in genetic science and not the expertise in plant
breeding.
A further example of the way in which these lexicons are manipulated
is seen in connection with the Human Genome Project.4" The National
Institutes of Health (NIH) have filed for thousands of patents on genetic
sequences and partial sequences. The US Patent Office has thus far refused
43. All citations taken from the on-line version of GATT, received via internet. References will
be made by section and article rather than page.
44. This has been a major concern of organizations such as Genetic Resources Action
International (GRAIN) and the Rural Advancement Fund International (RAF).
45. Pat Mooney, John Moore's Body, in 217 NEW INTERNATIONAST, at 8 (1991).
46. Id. at 9.
47. There are numerous discussions of the Human Genome Project. Seeeg., SHELDON KELVES,
THE CODE OF CODES: ScIETImFc AND SociAL IssuEs IN THE HUMAN GENOME PROJECT (1992).
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patents based upon the lack of "novelty." The NIH has reapplied claiming that
the "novel" step is showing what the genetic sequence "expresses." Nothing
new has been added. All that has happened is that a new minimalist definition
of "information" is being employed which says that identification is
information, and thus, patentable. Time will tell whether or not the Patent
Office will accept this new interpretation.
Section 5 of the GATT continues:
2) Parties may exclude from patentability inventions,
the prevention within their territory of commercial
exploitation of which is necessary to protect the
order public or morality, including to protect
human, animal or plant life or health or to avoid
serious prejudice to the environment, provided that
such exclusion is not merely because exploitation is
prohibited by domestic law.
3) Parties may also exclude from patentability:
a) diagnostic, therapeutic and surgical methods
for the treatment of humans or animals.
b) plants and animals other than
microorganisms and essentially biological
processes for the production of plants or
animals other than non-biological and
micro-biological processes. However,
parties shall provide for the protection of
plant varieties either by patents or by an
effective sui generis system or by any
combination thereof. This provision shall
be reviewed four years after the entry into
force of this agreement.
These paragraphs are ostensively about what can be excluded from
patentability. The most striking thing about them are those things which are
excluded from exclusion. In fact, the section opens the door for the
recognition of the patentability of life forms. In so doing, the GATT becomes
the first full-scale international agreement to recognize that life forms are
patentable. It does this in an ambiguous and subtle fashion. The key term is
"microorganisms." First, the term itself is very ambiguous. There are no clear
legal definitions as to what are and are not to count as "microorganisms."
After all, who cares about microorganisms? A very important principle is
being established here: life forms are patentable. Section 5(3) does not stop
there. It goes on to exclude from the exclusions "non-biological and micro-
19941
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biological processes. "4' Again, this is very ambiguous. What is included
under "non-biological" processes is never specified. On the other hand, the
reference to "micro-biological" process is not mysterious. Interpreted in its
most simple terms "micro-biological" would include genetic engineering, and
if the process is patentable then the product that the process creates can be
owned.
The rest of the paragraph is even more ambiguous. It states that
"parties shall provide for the protection of plant varieties ... by sui generis
systems." But this has to be read in the light of paragraph 1, which limits
criteria of "new" and the involvement of an "inventive step." It is not at all
clear what is and is not being protected here. The same can be said of the
stipulation concerning sui generis modes of protection. What these might be
and what might happen if and when they conflict with the GATT is not made
clear. What is clear is that, given the GATT, there would have to be real
limits to how far such local or regional instruments could go. This raises
questions as to what happens when the intent and specifics of UNCED or
local/regional/national priorities and GATT come into conflict. Again, it is
to the institutional sites that we must look for our clues. One of the
mechanisms which the GATT proposes is that when such conflicts exist, those
conflicts shall be adjudicated by means of GATT tribunals.
The final sentence about the review of the process four years from
inception is again key for the bioindustry. If its strategy is an incremental one
which begins with the recognition of the patentability of microorganisms and
microbiological processes, then moves to plants, then to animals and finally to
human beings, then a review of the policy after only relatively few years is
crucial.
Most of what we find in GATT (and NAFTA) is not new. We
already have recognition of the patentability of life forms in the United States
and Europe.49 The importance of GATT is threefold: first, it sets the context
and the terms of the discourse as being exclusively the marketplace; second, it
48. See supra note 44, § 5, Art. 27, 3(b) of the Dunkel Draft.
49. The first case involved scientist Ananda Chakrabarty who filed for the first patent on a
biotechnological invention in 1972. His application was based upon two points of requested
ownership: (1) the tangible microorganism and (2) its possible uses. See Diamond v. Chakrabarty,
447 U.S. 303, 65 L. Ed.2d 144 (1980). The patent was finally granted in 1981. In 1988 two
scientists at Harvard "invented" and patented the Oncomouse which entailed the insertion of an
oncogene into a mouse so that it would develop cancerous tumors. U.S. Patent, Patent Number:
4,736,866, April 12, 1988. See 1989 OFF. TECH. ASSESSMENT NEW DEVELOPMENTS IN
BIOTECHNOLOGY: PATENTING LIFE, SPECIAL REP., OTA-BA-370. The Supreme Court of the
U.S. has stated that anything which results from human activity (inventions) is patentable,
including superior life forms. Diamond v. Cbakrabarty, 447 U.S. 303. The European Patent
Office has also granted a patent on the Oncomouse. EtIR. PARL. REP. BIOETHICS IN EUROPE
(Scientific and Technological Options Assessment (STOA)) (1992).
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seeks to establish uniform patent regimes for all of those who would
participate in those global markets; and third, it establishes a well-defined
regime of retributive responses for failure to comply with these regulations.
One of the many challenges facing the international lawyer will be in
cases where UNCED (or even local/regional/national environmental
standards) and GATT are in conflict. Such cases are inevitable and while
GATT is highly ambiguous when it comes to the definitions of such things
as microorganisms, it becomes very specific when it comes to the retributive
mechanisms for those who do not follow its dictates. On the other hand,
mechanisms of enforcement are the weakest part of UNCED. One of the
crucial questions for the future of both UNCED and GATT is the
establishment of mechanisms of adjudication which strike some balance
between the demands and needs of sustainable development and those of open
markets. The GATT (or WTO) believe that this should remain within its
administrative purview, while others believe that something like a World
Environmental Court needs to be established.
What we see emerging here is a totally new theory of property appropriate
to the new age. The new legal battlefields upon which the new theories of
property and property rights will be shaped, are Intellectual Property Rights
(IPR) and Trade Related Intellectual Property Rights (TRIPS). IPR covers a
wide range of issues, including copyrights, trademarks, encrypted satellite
signals, sound and video recordings, layout designs of semiconductor integrated
circuits, trade secrets, industrial designs and patents. I want to focus the
discussion here by concentrating upon patents, particularly as they pertain to
biotechnology, as it is here that we can see the radical previous notions of
property and property rights. It could be argued that the colonization and
exploitation of the undeveloped world was carried out because the West or
North had a theory of property and ownership long before those other
countries did. By the time they awakened to the importance of property and
to what they had given away, it was too late. The new mode of property is
"information," and, once again, those who are on the cutting edge and in
control of the technologies are defining and delimiting what will and will not
count as informational property well in advance of those who lack the
development to see the long-term implications. Biotechnology exposes a
legal quagmire as well as a moral one. The bioindustry is seeking legal
protection in the form of intellectual property rights and the patenting of life
forms in order to control the financial return from the products which they
make from re-engineered DNA. As would be expected, the arguments which
emerge from the bioindustry are economic arguments and again, the stakes are
high. The bioindustry estimates that it requires on the order of $200,000,000
United States dollars to develop and bring to market a single genetically
engineered product. Given the difficulty for companies which have invested
such huge sums to control the distribution and reproduction of their products,
it is not unexpected that they want patent protection which require the end
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user to pay a "royalty" to the company for each new replication. How such
"information" can be controlled, royalties computed, and to what degree this
information becomes part of the public domain are indeed very complicated
problems. Patents are presently the principal legal mechanism for ownership
of intellectual property and biotechnical information. But new, complicated
issues concerning the differences in process patents versus product patents,
novelty issues (one of the precedented criteria for patentability), and
reproducibility (which also involves the relationships between developing and
developed countries), are raising questions as to whether or not patents (as a
mechanism) are able to accommodate the new forms and issues involved here.
The key to assessment goes beyond confronting the question of the
notion of property (which is both a legal as well as an ethical issue) which is
being employed or developed within biotechnology. In order to begin this
process, I want to return to what I have called the new lexicons. How those
lexicons are set up is the crucial issue. As I have said, the issue is that these
new lexicons will determine what will count as information (and thus be able
to be owned) and what will not. As an example, note the previously cited
case of the plant breeders in West Africa who cannot "own" the "information"
which has come to them through generations of plant breeding (as it is not
"property"); contrast that with the genetic scientist who can determine the
genetic characteristics (the information codes) of that breeding process and can
be granted a patent. The lexicon is established to the advantage of those who
possess the higher technology, and this is obviously the developed countries.
Again my point is not to vilify the bioindustry, but simply to point
out the forces that are constituting the terms of the discussion of
biotechnology in some of the most important institutional sites. By
determining the definitions of "information" in the new lexicon at the outset,
the bioindustry gains control over the marketplace of information. By
establishing the criteria which will determine what is and is not able to be
owned, it creates a structured marketplace in which participation is dependent
upon technical competencies and their associated criteria. We can hardly blame
them for operating out of self-interest, but we should blame ourselves and our
institutions which are supposed to safeguard public welfare and which have
not raised the kind of questions which need to asked about the distributions
of power in this emerging new age.
Likewise, there exists concerns for the preservation of species and
biodiversity. 0 There are various strategies for the maintenance of biodiversity
50. In fact, we are entering a new era of bio-politics; new and disturbing forms of
knowledge/power configurations which decenter the meaning of terms which have been relatively
stable in the past such as "nature" and "species." Taking the last of these first, biotechnology
renders the traditional uses of terms such as nature and species meaningless. Nature has always
been a limit concept. It has provided us with a set of categories and a ground which more than
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and the preservation of species. One view on the preservation of species and
the maintenance of biodiversity is holistic in nature. To preserve a species
demands that the entire ecosystem within which it cohabitats be maintained.
Ontologically, a species is seen in terms of that set of relationships
which it maintains with the other participants of that ecosystem. It is this
strategy which is pursued by the UNCED Biodiversity Convention. Within
what might be called the "mechanistic worldview," we find that a species is
viewed in terms of a substance ontology. Preservation is accomplished if a few
examples of the species are maintained in holding facilities. These facilities may
be limited attempts to preserve or duplicate ecosystems or they may be zoos
or animal theme parks. The animal is discursively construed as substance.
This means that as long as one material example is preserved somewhere the
species is not extinct.
Within a cybernetic/biotechnical worldview, the preservation of a
species can be accomplished by preserving its genetic code in a gene bank.
Ontologically, a species is reduced to that information encoded in its DNA;
wholly apart from its relationship within an ecosystem and even apart from
the need to preserve a living example. It should be noted that gene banks are
presently being established all over the world, and that one of the primary
claims they make to legitimate their existence is the preservation of species.
Above all of this hangs the profound philosophical question of
whether a species has a right to exist, and whether this should have some type
of international legal standing. Do we preserve species only because they are
genetic resources for us or do they have value in themselves? One argument
made on behalf of biotechnology is that it will help in the preservation of
species through bio-prospecting. Since global genetic diversity is its resource
pool, it is obviously to its advantage to conserve it. Thus bio-prospecting is an
argument for preservation. However, at some point it becomes necessary to
ask whether we want to establish an international legal principle which says
we preserve useful species, and allow those which are deemed not useful to
become extinct. Granted, this is a harsh statement of the issue, nevertheless,
I would argue that it is one which those working in the area cannot avoid.
Finally, there is the claim by the bioindustry that it will add to
biodiversity both by working to maintain the present biodiversity (because it
is the industry's resource base) and by adding to biodiversity through the
any other concept has been transcultural and transhistorical. Likewise for the term species, with
the exception for the rapid disappearance of species due to ecological devastation in the modem
period, the concept of species has represented a relatively stable limit to thought and practice.
Within the new discursive regime of biotechnology both terms become virtually meaningless as
limit concepts. Transgenic organisms do not exist in nature. The slow evolutionary process by
which nature introduced new species and new organisms has now been irrevocably altered. The
number of new species which might be introduced is limited only by the genetic resource base and
human imagination.
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introduction of new organisms and species. Foucault's ideas of
knowledge/power regime are thus taken, in some scenarios, to nightmarish
proportions. With the introduction of new and more efficiently designed
organisms into already overstressed ecosystems, survival of the fittest becomes
a game fixed in favor of the laboratory produced contestants. Furthermore,
under the protection of the patenting of these life forms, corporations will not
just own an animal, plant or organism, but an entire genetic line. It becomes
possible to genetically "own" an entire species. This leads one to imagine a
future in which the biodiversity remaining on the planet comes primarily from
the laboratories. When one adds to this the fact that the industry is now
seeking to be able to patent anything it discovers, we are left in a world where
the biodiversity of the planet is entirely owned by various patent holders.
Nor is this scenario limited to the nonhuman. There are already cases
involving the patenting of human life forms which add disturbing new
chapters to what Foucault has called the "political technologies" of control of
the body. The case of John Moore's spleen is just one example.-1 Moore had
his cancerous spleen removed at UCLA. It was subsequently determined that
his spleen had certain genetic characteristics which made it useful for
developing a "cell line." That cell line was sold to a biotech firm, which in
turn sold part of it to the giant Swiss concern, Sandoz. Moore went to court
to demand a portion of the profits which had been derived from his spleen.
The lower court found in his favor but the California Supreme Court found
that the companies had no fiduciary responsibility to Moore. 2 (It did,
however, allow him to sue his doctors for not informing him of what they
were doing.) Moore's spleen (or, more specifically the cell line developed from
it) had become the "intellectual property" of those who had identified its
information and use-value. 3 John Moore's body had become a piece of
intellectual property over which he has lost "ownership" rights. 4
There is also the recent patent application by the Secretary of Commerce
of the United States for a cell line developed from the genetic structure of the
51. See ANDREW IKMRELL, THE HUMAN BODY SHOP: THE ENGINEERING AND MARKETING OF
LIHF, ch. 15 (1993).
52. See Moore v. Regents of University of California, 215 Cal. App. 3d. 709, 249 Cal. Rptr. 494
(1988).
53. See Moore v. Regents of University of California, 215 Cal. App. 3d. 709, 249 Cal. Rptr. 494
(1988), overruled by Moore v. Regents of University of California, 51 Cal.3d 120, 793 P.2d 479
(Cal. 1990).
54. Mooney, supra note 45, at 217.
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Guaymi Indians of Panama (U.S. Patent Application 9108455).1s This was
done without the knowledge of the Guaymi Indians (although the patent
application reads "Human T-Lymphotroic Virus Type 2 From Guaymi Indians
in Panama" and without any intention of compensation for the use of their
genetic structure as an economic resource. This patent application must be
seen in the context of a much broader project called the Human Genome
Diversity Project which is gathering genetic materials from indigenous peoples
all over the planet.5 6 When added to the thousands of patents applied for by
the National Institutes of Health in connection with the Human Genome
Diversity Project we begin to see the dimensions of this new age.
What does it mean to "own" the genetic structure of a person, of a
tribe of people or of humanity? What kind of rights do we have over our own
genetic structure? Is property to be defined based purely on techno/scientific
superiority? How should equitable distribution of profits be structured in such
cases? And the basic question behind all of this: should the patenting of life
forms be allowed at all? What is clear is that there is a range of profound
cultural, social, ethical even religious questions which go beyond the legal
issues when it comes to biotechnology.
Finally, there is the international issue of the release of genetically
modified organisms (GMO's) into the environment. Not only is this an issue
which can be raised with regard to laboratory construction (an international
rather than a domestic issue) but also with regard to the experimental release
of GMOs. While there are regulations in the United States limiting
experimental release of GMOs and the type of testing of genetically created life
forms, most developing countries have no such regulations pertaining to either
laboratory construction or to experimental releases. This has led critics of the
bioindustry to fear that developing countries will become experimental
dumping grounds. The long term effects of this scenario upon the indigenous
biodiversity cannot be known.
I would argue that all of these issues move us beyond the legal and
into the ethical. It is often argued that the larger cultural, ethical, and
environmental issues would seem more appropriate for the government official,
the professional ethicist or even the futurologists. This is due to the fact that
the lawyer's responsibility is advocacy: the representation of the client's
55. U.S. Patent Office Publication #WO 0208784 Al, May 29, 1992, APP. # US 9108455, Priority
Application # US 612,707; 11/15/90. Applicant United States of America represented by The
Secretary, United States Department of Commerce, Washington, D.C. Inventors: LAIRMORE,
Dale; KAPLAN, Jonathan; IPC Codes C12N 5/00; C12N 7/00; C12Q 1/70; A61K 49/00. Image
Disc Number. Espace World Disc# 1992/020.
56. This information comes from Pat Mooney at the Rural Advancement Foundation
International and will be published in a forthcoming article in DEVELOPMENT DIALOGUE. While
it appears that the controversy surrounding this patent application has caused the government to
withdraw, it is only a matter of time before such patent applications are commonplace.
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interests, whatever may be those interests. But with respect to biotechnology
and its future impacts upon biodiversity and society, a greater responsibility
is at play here. Given that these long-term impacts are potentially so dramatic,
it would be surprising if the lawyer did not find him or herself caught between
the short-term demands for profits, markets, etc. and the long-term
responsibilities to future generations.
While it is easy to place this greater responsibility aside in the name
of advocacy, the question remains as to whom the responsibility belongs. It
cannot be argued that it is the responsibility of policy makers as the
disposition of biotechnology for the future will clearly not be determined as
a matter of definitive policy. Rather, it will be determined in terms of
contracts between parties which will test the limits of the interpretive
possibilities of the very general principles established in GATT or UNCED.
Again, the point is that virtually everything that the international lawyer does
with regard to biotechnology and biodiversity will be precedent-setting. The
cumulation of these precedents will establish overall trajectory of where we
will take this dramatic new technology.
As I have argued, options exist in terms of the principles to which
appeals can be made in choosing these directions. The challenge is to strike
a balance between responsibility as an advocate of the client's short-term
interests and responsibility to the longer-term interests of sustainability.
Finding this balance is likely to require new forms of cooperation with those
both inside and outside of the client's organization and a good deal of creative
thinking on the part of the lawyer and those with whom she or he works.
What is unacceptable is to ignore or place in abeyance the questions of the
long-term effects of biotechnology and of the precedents which are established
in the present.
We can all agree that the long-term effects of the last great
technological revolution of the Industrial Revolution have not been good
when it comes to the environment and biodiversity. Hopefully as we enter
this new biotechnological revolution, we will do so in a more conscious and
conscientious fashion than we did the first time. It would seem to be
undeniable that the long-term potential of biotechnology for both good and
bad is unprecedented. For all of the failures of the UNCED process, it does
represent a new level of global self-awareness and a commitment to consider
the future as part of current decisions. It mandates this responsibility to future
generations as part of everyone's professional responsibility. Sustainability does
not need to be a bad or threatening word for business or government. It is
one which requires that new solutions be sought which take into account this
new awareness of the future. The challenge is to find ways to wed the visions
of sustainability to those of open markets. As we move into this new age
characterized by information and internationalization, the international lawyer
is uniquely positioned to impact the course we chart for the twenty-first
century. But in order to do so, he or she must be willing to engage in these
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broader questions. For it is through engagement, at this level, that guidance
for the crucial legal directions will emerge.

